X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.gilead.com/news-and-press/press-room/press-releases/2024/4/gilead-sciences-announces-first-quarter-2024-financial-results
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/fda-expands-indication-for-gileads-vemlidy-tenofovir-alafenamide-to-treat-chronic-hbv-infection-in-pediatric-patients-as-young-as-six
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217037
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-tablets-59973.pdf
https://www.fiercepharma.com/marketing/dovato-advert-dispute-between-viiv-and-gilead-escalates-feds-after-self-regulatory
https://www.freepressjournal.in/business/lupin-receives-approval-from-usfda-for-tenofovir-alafenamide-tablets
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214226
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-tentative-usfda-nod-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-tablets/articleshow/97482041.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214544
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216875
https://www.pharmaceutical-technology.com/news/gilead-ec-hiv-treatment/
https://www.fiercepharma.com/pharma/gileads-vemlidy-enters-pediatric-hepatitis-b-arena-fda-green-light
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214058
https://www.fool.com/investing/2022/09/14/my-biggest-worry-about-gilead-sciences/
https://www.fiercepharma.com/pharma/gilead-pads-case-top-seller-biktarvy-hivhepatitis-b-coinfection
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-usfda-nod-to-market-drug-used-to-treat-chronic-hepatitis-b/articleshow/90911465.cms
https://www.businesswire.com/news/home/20201201005450/en/Gilead-Canada-Announces-Notice-of-Compliance-for-DESCOVY%C2%AE-emtricitabine-tenofovir-alafenamide-for-HIV-Pre-Exposure-Prophylaxis-PrEP
https://www.biospectrumasia.com/news/98/16885/gilead-to-present-antiretroviral-therapies-at-virtual-apacc-2020-conference.html
https://www.fiercepharma.com/marketing/gilead-slammed-for-misleading-claim-biktarvy-against-gsk-s-rival-hiv-drug
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-seeks-clarification-on-gileads-drug-pricing-plea/articleshow/73788094.cms
http://www.pharmabiz.com/NewsDetails.aspx?aid=120660&sid=1
https://endpts.com/a-uspto-legal-adviser-is-off-controversial-gilead-hiv-case-after-activists-allege-tweets-show-bias/
https://www.fiercepharma.com/marketing/gilead-s-converting-truvada-prep-users-to-descovy-faster-than-expected-analyst
http://www.pharmatimes.com/news/vemlidy_tackles_hep_b_in_late-stage_trials_1316991
https://www.raps.org/news-and-articles/news-articles/2019/11/us-sues-gilead-over-hiv-drug-patents
https://www.biospectrumasia.com/news/48/14247/china-nmpa-approves-biktarvy-to-treat-hiv-1-infection.html
https://in.reuters.com/article/us-gsk-hiv/gsks-dovato-meets-primary-goal-in-late-stage-hiv-study-idINKCN1U50KV
https://www.raps.org/news-and-articles/news-articles/2019/5/fda-unveils-34-new-and-revised-product-specific-dr
https://www.fiercepharma.com/marketing/j-j-sponsored-film-about-first-aids-ward-san-francisco-picked-up-for-broader-distribution
https://en.prnasia.com/releases/apac/singapore-health-sciences-authority-approves-biktarvy-r-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection-237107.shtml
https://www.businesswire.com/news/home/20181118005058/en/China-National-Medical-Products-Administration-NMPA-Approves
https://www.raps.org/news-and-articles/news-articles/2018/8/aids-foundation-petitions-supreme-court-to-invalid?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2020%20August
https://www.gilead.com/news/press-releases/2018/6/european-commission-grants-marketing-authorization-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv1-infection
https://www.fiercepharma.com/corporate/gilead-strikes-back-at-gsk-positive-hiv-head-to-head-trial-data
http://www.pmlive.com/pharma_news/gilead_says_switching_studies_back_new_hiv_therapy_biktarvy_1225972
http://ir.contravir.com/news-releases/news-release-details/contravir-pharmaceuticals-announces-txltm-has-been-granted
http://www.pharmatimes.com/news/us_green_light_for_gileads_hiv_combo_1220972
https://endpts.com/with-hep-c-cash-dwindling-gilead-gets-a-blockbuster-boost-from-an-fda-ok-of-hiv-triplet-biktarvy/
https://www.fiercepharma.com/financials/cvs-unitedhealthcare-formulary-moves-hit-sanofi-s-diabetes-sales-hard
https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mylan-wants-to-capture-chronic-hep-b-market/articleshow/61987344.cms
http://www.businesswire.com/news/home/20171025005612/en/Janssen%E2%80%99s-New-Darunavir-Based-Single-Tablet-Regimen-SYMTUZA%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.pharmacompass.com/pdf/news/janssen-cilag-international-generic-symtuza-receives-approval-in-europe-1506487967.pdf
http://www.prnewswire.com/news-releases/fda-accepts-supplemental-new-drug-application-for-eisais-lenvatinib-for-the-treatment-of-liver-cancer-300526147.html
http://www.pharmatimes.com/news/ec_approves_janssens_symtuza_1206421
Market Place
Share 
